drugset
drugset / Trial / NCT03854617

A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer

NCT03854617 ↗

Phase 2 Unknown 172 enrolled Chinese Academy of Medical Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open-label, parallel, multi-center study, aims to evaluate the efficacy and safety of metronomic chemotherapy with oral Navelbine versus intermittent oral Navelbine in female patients with HER2 negative Metastasis Breast Cancer.

Timeline

Start
2019-02-20
Primary completion
2021-12-20
Completion
2025-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Vinorelbine Small molecule 50 mg Oral
Subject Vinorelbine Small molecule 80 mg/m2 Oral

Indications

Her2-receptor negative breast cancer